Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab + F007 in R/R DLBCL
NCT05178836Phase 2Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rulonilimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Objective Response Rate at 16 weeks. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05178836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178836.